Formulary Search Results for: FLUTICASONE FUROATE AND VILANTEROL
3.2.2 Combination inhaled devices - View Category
Restrictions:
Restricted to severe COPD (FEV1 <50% predicted normal)
Prescribing Notes:
To prevent confusion, prescribe inhaler devices by brand name.
3.2.2 Combination inhaled devices - View Category
Restrictions:
COPD: The symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with an exacerbation history despite regular bronchodilator therapy is restricted to use in patients with severe COPD (FEV1 <50% predicted normal).
Asthma: The regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonists
Prescribing Notes:
To prevent confusion, prescribe inhaler devices by brand name.
- Fluticasone furoate is a high-potency inhaled steroid (with a dose of 92 micrograms once daily broadly equivalent to 250 micrograms twice daily of fluticasone propionate). When used for asthma, due consideration for the likelihood of step-down should be given prior to initiation as there are no available step-down options containing a dose lower than 92 microgram of fluticasone furoate.
- Prescribers should be aware that the fluticasone furoate contained in this preparation is not equivalent in terms of dosing to fluticasone propionate.
- The Summary of product characteristics for this preparation advises on dose equivalence in section 4.2.
- The name of this device may inadvertently lead patients to confuse it as a 'reliever'. Careful counselling to avoid overuse is advised.
- Only the 92/22 microgram strength is licensed for COPD
12.2.1 Drugs used in nasal allergy - View Category
Restrictions:
Restricted to specialist initiation. Restricted to allergic rhinitis patients in whom beclomethasone and budesonide have been ineffective or not tolerated.
12.2.1 Drugs used in nasal allergy - View Category
Restrictions:
Restricted to specialist initiation where fluticasone nasal sprays should be reserved for patients in whom beclometasone and budesonide have been ineffective or not tolerated. Flixotide Nasules® are not included in the GGC Formulary.
12.2.1 Drugs used in nasal allergy - View Category
Prescribing Notes:
Mometasone nasal sprays should be reserved for patients for whom preferred list options have been ineffective or not tolerated.
2.8.4 Reversal of anticoagulation - View Category
Restrictions:
Restricted to use only on the advice of a Consultant Haematologist for the reversal of anticoagulation in adults treated with a direct factor Xa inhibitor where there is life-threatening or uncontrolled bleeding. In addition, use should be in accordance with the local protocol (in development).
13.4.6 Potent - View Category
13.4.6 Potent - View Category
12.2.1 Drugs used in nasal allergy - View Category
Restrictions:
For use in patients who require both a nasal steroid and nasal antihistamine and where compliance is considered to be an issue.
Prescribing Notes:
Patient should have tried monotherapy with a nasal steroid for 6-12 weeks first with no benefit.